S.Amdt. 3213

SA 3213. Mr. TUBERVILLE submitted an amendment intended to be
proposed by him to the concurrent resolution S. Con. Res. 14, setting
forth the congressional budget for the United States Government for
fiscal year 2022 and setting forth the appropriate budgetary levels for
fiscal years 2023 through 2031; which was ordered to lie on the table;
as follows:

At the end of title III, add the following:

SEC. 3___. DEFICIT-NEUTRAL RESERVE FUND RELATING TO A TAX
CREDIT FOR DOMESTIC INVESTMENT IN MANUFACTURING
OF DRUGS AND MEDICAL DEVICES.

The Chairman of the Committee on the Budget of the Senate
may revise the allocations of a committee or committees,
aggregates, and other appropriate levels in this resolution,
and make adjustments to the pay-as-you-go ledger, for one or
more bills, joint resolutions, amendments, amendments between
the Houses, motions, or conference reports relating to
Federal income taxes, which may include establishing a tax
credit of 20 percent of net income from new domestic
investments in advanced manufacturing equipment or machinery
used in the United States to manufacture drugs, medical
devices, or biological products, by the amounts provided in
such legislation for those purposes, provided that such
legislation would not increase the deficit over either the
period of the total of fiscal years 2022 through 2026 or the
period of the total of fiscal years 2022 through 2031.
______